BeiGene Trial of Lung-Cancer Treatment Reaches Primary Endpoints

By Ben Glickman BeiGene's trial of the use of tislelizumab to treat resectable non-small cell lung cancer, when combined with chemotherapy, reached its dual...

Related Keywords

Ben Glickman , ,Article Normal ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Specialized Drugs Medications ,Cancer ,Political General News ,Chemotherapy Radiotherapy Immunotherapy ,Health ,Medical Conditions ,Medical Treatments Procedures ,Synd ,Beigene ,Bgne ,Political ,General News ,Chemotherapy ,Radiotherapy ,Immunotherapy ,Medical Treatments ,Procedures ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,